Integrating Multi-Assessment Protocols into Practice

描述：（申请人提供） 药物滥用治疗领域的国家领导人认识到， 建立有效的治疗方法，并将这些治疗方法推广到更多的人 寻求治疗这反映在建立NIDA临床 试验网络（CTN）通过大规模临床试验研究有效性 试验，并在建立CSAT实践研究协作 （PRCs）是研究与实践之间的桥梁。这些承诺的全部 然而，如果不采取干预措施， 有效性被应用于临床实践。虽然现有文献 关于影响组织变革的因素的评论， 治疗创新的采用，以及研究与实践之间的差距， 没有系统的努力来整合这些文献， 测量策略，并使用这些措施，研究干预措施的采用 在多个临床试验中。 这是一个建议，制定和应用多层次评估协议（MAP） 调查行为导向的药物滥用治疗 社区提供者采取干预措施， 多中心临床试验。拟议项目将建立程序， 调查研究为基础的治疗干预措施在 治疗领域，确定干预措施采用的障碍，并确定 增加或减少采用可能性的因素。创新和 在矩阵甲基苯丙胺的背景下实地测试MAP策略 多中心临床试验，这不是NIDA CTN的一部分。然后我们将 将MAP应用于CTN动机增强疗法/动机 采访目前处于初期阶段的临床试验。长期项目 目标是建立战略，用于国家CTN，这将 增加采用临床试验干预措施的可能性。 这是最早可能应用的收养评估 方法直接到CTN节点的活动，并确定因素， 促进或延迟采用CTN干预措施。使用改进的MAP CTN背景下的战略为MAP的扩展奠定了基础， CTN节点，以及未来的随机化设计，其中特定干预 采用技术可以通过经验进行检验。

DESCRIPTION: (provided by applicant) National leadership in field of drug abuse treatment has recognized the need to establish effective treatments, and to extend those treatments to more persons seeking treatment. This is reflected in establishment of the NIDA Clinical Trial Networks (CTNs) to study effectiveness through large-scale clinical trials, and in the establishment of CSAT Practice Research Collaboratives (PRCs) to bridge between research and practice. The full promise of these efforts, however, cannot be realized unless interventions with demonstrated effectiveness are adopted into clinical practice. Although available literature comments on factors influencing organizational change, factors influencing adoption of treatment innovation, and the gap between research and practice, there are no systematic efforts to integrate this literature, develop measurement strategies and, using these measures, study intervention adoption in multi-site clinical trials. This is a proposal to develop and apply a Multi-level Assessment Protocol (MAP) to investigate the extent to which behaviorally oriented drug abuse treatment interventions are adopted by community based providers participating in multi-site clinical trials. The proposed project will establish procedures for investigating how well research-based treatment interventions are adopted in the treatment field, identify barriers to intervention adoption, and identify factors that increase or decrease likelihood of adoption. We will develop and field test a MAP strategy in the context of the Matrix methamphetamine multi-site clinical trial, which is not a part of the NIDA CTN. We will then apply the MAP to the CTN Motivational Enhancement Therapy/Motivational Interviewing clinical trial currently in nascent stages. The long-term project goal is to establish strategies, for use in the national CTN, which will increase the likelihood of adoption of clinical trial interventions. This represents the earliest possible application of adoption assessment methods directly to the activities of CTN nodes, and identifies factors that facilitate or retard adoption of CTN interventions. Use of a refined MAP strategy within the CTN context sets the stage for expansion of the MAP across CTN nodes, and for future randomized designs in which specific intervention adoption technologies can be empirically tested.